Level Biotechnology
Level Biotechnology Inc. engages in marketing and distributing cell culture, immunology, and molecular biology products in Taiwan. It markets and distributes biomedical precision equipment. The company also provides services in the areas of mammalian and genetic toxicology, pharmacology, biocompatibility, and model animal production. In addition, it offers preclinical research services to the bio… Read more
Level Biotechnology (3118) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.021x
Based on the latest financial reports, Level Biotechnology (3118) has a cash flow conversion efficiency ratio of 0.021x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$11.81 Million) by net assets (NT$562.82 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Level Biotechnology - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Level Biotechnology's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Level Biotechnology Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Level Biotechnology ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Lakeside Holding Limited Common Stock
NASDAQ:LSH
|
-0.037x |
|
brooqLy Inc.
PINK:BRQL
|
0.397x |
|
Defence Therapeutics Inc
OTCQB:DTCFF
|
0.512x |
|
HBR Realty Empreendimentos Imobiliários S.A
SA:HBRE3
|
0.080x |
|
Oba Makarnacılık San As
IS:OBAMS
|
0.222x |
|
Opticis Company Limited
KQ:109080
|
0.013x |
|
Saga Metals Corp.
V:SAGA
|
N/A |
|
Wooyang Co. Ltd
KQ:103840
|
0.073x |
Annual Cash Flow Conversion Efficiency for Level Biotechnology (2017–2024)
The table below shows the annual cash flow conversion efficiency of Level Biotechnology from 2017 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$559.91 Million | NT$64.10 Million | 0.114x | -10.41% |
| 2023-12-31 | NT$549.47 Million | NT$70.21 Million | 0.128x | +6.51% |
| 2022-12-31 | NT$542.40 Million | NT$65.07 Million | 0.120x | -58.09% |
| 2021-12-31 | NT$544.84 Million | NT$155.95 Million | 0.286x | +82.08% |
| 2020-12-31 | NT$529.43 Million | NT$83.23 Million | 0.157x | -25.92% |
| 2019-12-31 | NT$513.75 Million | NT$109.02 Million | 0.212x | +295.34% |
| 2018-12-31 | NT$498.78 Million | NT$26.77 Million | 0.054x | -60.68% |
| 2017-12-31 | NT$522.28 Million | NT$71.29 Million | 0.136x | -- |